The Opposite Functions of CD30 Ligand Isoforms [PDF]
Current Issues in Molecular BiologyTNFSF8/CD30 ligand is a TNF superfamily member expressed on several major immune cell types, including activated monocytes, B, and T cells. The signaling of CD30 ligand through its cognate CD30 receptor has been shown to have effects on cell ...
Ignat Printsev +2 more
doaj +6 more sources
Immunoexpression of CD30 and CD30 ligand in deciduas from spontaneous abortions
European Journal of Histochemistry, 2009 In the present study, using immunohistochemistry, we studied the expression of CD30 and CD30-L in 35 deciduas obtained from women following elective abortion during normal physiological gestation and in 60 deciduas obtained from women after spontaneous ...
M Trovato +6 more
doaj +6 more sources
Beyond CD30: Dual-Targeting of Malignant and Regulatory T Cells by Brentuximab Vedotin Remodels the Lymphoma Microenvironment and Overcomes Resistance via BCL2 Inhibition in Mycosis Fungoides. [PDF]
Adv Sci (Weinh)Single‐cell RNA analyses of paired lesions from CD30+ mycosis fungoides patients demonstrate that brentuximab vedotin (BV) induces immunogenic cell death in both CD30+ and CD30− malignant T cells. BV also targets regulatory T cells and remodels tumor microenvironment, while resistance is driven by impaired IFN responses, drug efflux, and BCL2 ...
Jiang Y +8 more
europepmc +2 more sources
CD30 Expression in Neoplastic Mast Cells and the Presence of CD30+, CD3+, and PAX-5+ Tumour-Infiltrating Lymphocytes as Prognostic Markers in Canine Cutaneous Mast Cell Tumours. [PDF]
Vet Comp OncolABSTRACT Canine cutaneous mast cell tumour (MCT) is the most common skin neoplasm in dogs, with histopathology serving as both the diagnostic and primary prognostic tool. However, identifying reliable biomarkers is essential for improving clinical decision‐making.
Ramos FR +6 more
europepmc +2 more sources
Targeting CD30L in B-cell non-Hodgkin lymphoma: novel peptide conjugates and their therapeutic potential [PDF]
Molecular CancerBackground B-cell non-Hodgkin lymphoma (B-NHL) constitutes the majority of NHL cases. Patients with B-NHL often experience multiple recurrences, necessitating several lines of antitumor therapy, and develop drug resistance.
Chaowen Shi +7 more
doaj +2 more sources
Breast implant-associated anaplastic large cell lymphoma: a diagnostic challenge [PDF]
Revista Brasileira de Cirurgia Plástica, 2020 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a provisional entity with morphological and immunophenotypic characteristics indistinguishable from ALK-negative anaplastic large cell lymphoma (ALCL).
Ana Paula De-Azambuja +4 more
doaj +1 more source
Tyrosine kinases in nodal peripheral T-cell lymphomas
Frontiers in Oncology, 2023 Nodal peripheral T-cell lymphomas (PTCL) are uncommon and heterogeneous tumors characterized by a dismal prognosis. Targeted therapy has been proposed.
Pier Paolo Piccaluga +3 more
doaj +1 more source
Current and emerging treatment options in primary mediastinal B-cell lymphoma
Therapeutic Advances in Hematology, 2021 Previously considered a subtype of diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) is now recognized by the World Health Organization as an independent entity. PMBCL has clinicopathologic features that are separate from
Bita Fakhri, Weiyun Ai
doaj +1 more source
Updating targets for natural killer/T-cell lymphoma immunotherapy
Cancer Biology & Medicine, 2021 Natural killer/T-cell lymphoma (NKTCL) is a highly invasive subtype of non-Hodgkin lymphoma, typically positive for cytoplasmic CD3, CD56, cytotoxic markers, including granzyme B and TIA1, and Epstein-Barr virus (EBV).
Weili Xue, Mingzhi Zhang
doaj +1 more source
Frontiers in Immunology, 2023 The extracellular domain of tumor necrosis factor receptors (TNFR) generally require assembly into a homotrimeric quaternary structure as a prerequisite for initiation of signaling via the cytoplasmic domains.
George Fromm +2 more
doaj +1 more source